LENZ Therapeutics, Inc. · NASDAQ:LENZ
LENZ Therapeutics — Investor Presentation (November 2023)
21 slides from LENZ Therapeutics's investor presentation, Nov 14, 2023
Slide 1: LENZ Therapeutics – November 2023
LENZ THERA PEUT I November 2023
Slide 2: LENZ Therapeutics – positioned for leadership in $3B+ market
LENZ THERAPEUTICS – positioned for leadership in $3B+ market Late stage exclusive aceclidine-based eye drop with potential of providing all day seamless vision for the vast majority of presbyopes Unique MOA Only miotic shown to achieve pupil sweet spot <2mm w/o myopic shift Profile Best-in-class 73%
Slide 3: Presbyopia, the inevitable loss of near vision
Problem Presbyopia, the inevitable loss of near vision Research shows adults over 50 lose on average 1.5 lines of near vision per 6 years1 Impacts 128M People in the US Impacts over Potential $3B+ Market 120M People in the US 3
Slide 4: Promise of a once-daily eye drop solution is welcomed by all age groups
Promise of a once-daily eye drop solution is welcomed by all age groups Adapting Early Busy Midlife Active Aging Seriously Consider Seriously Consider Seriously Consider 68% 62% 51% 4 – 7 days/wk Usage1 4 – 7 days/wk Usage1 4 – 7 days/wk Usage1 80% 79% 79% 45 – 54 55 – 64 +65 N=452 N=448 N=458 4 Sou
Slide 5: How the eye focuses light for near and distance vision, and the problem of presbyopia
How the eye focuses light for near and distance vision in the healthy eye, and the problem of presbyopia Distance vision Near vision for healthy eyes Near vision in Presbyopia The lens is in its native shape which The lens changes shape, known as The lens hardens with age, limiting enables far visio
Slide 6: Ideal presbyopia eye drop creates a pinhole pupil while avoiding a myopic shift
Ideal presbyopia eye drop creates a pinhole pupil while avoiding a myopic shift that impacts distance vision Create a pinhole pupil While avoiding a myopic shift Contracted Iris Muscle Pinhole Pupil FDA requires 3 lines of near vision improvement while not losing 1 or more lines of distance vision 6
Slide 7: Reducing pupil diameter below 2mm increases depth-of-focus and near vision
Research shows reducing the pupil diameter below 2mm dramatically increases depth-of-focus and near vision 7,8 Total Depth-of-Focus Near Vision Improvement Total Depth-of-Focus (D) 6 0.6 Lighting Conditions (cd/m2) Lines Improvement 20 (Dark) 5 0.5 200 (Office) 4 2000 (Cloudy Day) 0.4 Average 3 0.3
Slide 8: Aceclidine is the only pupil selective miotic
Aceclidine is the only pupil selective miotic6 Iris sphincter muscle Ciliary muscle Independence ratio EC50 (nmol/l) EC50 (nmol/l) ciliary to iris EC50 25,000 Longitudinal 28 Aceclidine 900 20,000 Circular 22 1,800 3,360 Longitudinal 1.9 Pilocarpine 2,840 Circular 1.6 Carbachol 106 574 Longitudinal
Slide 9: Uniquely achieving <2mm pupil without myopic shift
Uniquely achieving <2mm pupil without myopic shift4 Miotic pinhole effect achieved Corresponding myopic shift (iris sphincter muscle) (ciliary muscle) -0.17 Diopters myopia 2% Aceclidine 1.40 mm 0.078 mm lens shift 0.07 mm increase lens thickness -1.3 Diopters myopia 2% Pilocarpine 1.35 mm 0.234 mm
Slide 10: One diopter of myopic shift is meaningful
One diopter of myopic shift is meaningful 20/20 20/50 Perfect vision 1 Diopter myopic shift 20/40 20/40 Drivers test line 10
Slide 11: Addressable market is largest when pinhole effect is decoupled from myopic shift
Addressable market is largest when pinhole effect is decoupled from myopic shift Adapting Early Busy Midlife Active Aging Presbyopia market segments 40 – 54 yrs 55 – 64 yrs Over 65 yrs 31% 30% 39% Target Market Aceclidine 100% All Eyes / All Day Other <20% Early Presbyopes / Emmetropes miotics 11
Slide 12: Best-in-class potential
Aceclidine Preservative free eye drop The first and only pupil selective miotic with potential to provide all eyes, all day near vision improvement Best-in-class potential 12
Slide 13: INSIGHT trial compared LNZ100 and LNZ101 against vehicle on key variables
INSIGHT trial compared LNZ100 and LNZ101 against vehicle on key variables LNZ100 Study Design • Multicenter safety and effectiveness study 1.75% Aceclidine • 5 US Sites, 50+ Patients • Double-masked, randomized, crossover - Ready to use • Placebo controlled - Preservative Free Eye Drop • 10 hr durat
Slide 14: Pupil diameter within the sweet spot for hours
Pupil diameter within the sweet spot for 10 hours Pupil Size Near Vision Improvement Biomarker LNZ100 (n=49) LNZ101 (n=50) Placebo (n=51) 4.0 3.5 Average pupil size reduced to ~1.6mm at 30 minutes Pupil size (mm) 3.0 Pupil size correlates to lines of near vision 2.5 improvement 2.04 2.0 2.0 Average
Slide 15: Primary 1 hour endpoint met and 10 hours duration
Primary 1 hour endpoint met and 10 hours duration ≥3-Line % Improvement Over Time (No loss of 5 or more letters distance) LNZ100 (n=49) LNZ101 (n=50) Placebo (n=51) 73 73 Extended category leadership with best- 71 69 in-class data for efficacy and duration for 62 64 both LNZ100 and LNZ101 56 57 58 5
Slide 16: Secondary 1 hour endpoint met and 10 hours duration
Secondary 1 hour endpoint met and 10 hours duration ≥2-Line % Improvement Over Time (No loss of 5 or more letters distance) LNZ100 (n=49) LNZ101 (n=50) Placebo (n=51) 92 92 86 86 82 78 78 78 Both LNZ100 and LNZ101 provided 74 72 69 74 69 clinically meaningful 2 lines or more NV 68 improvement for al
Slide 17: No impact to distance vision in normal and low light
No impact to distance vision in normal and low light Distance Visual Acuity Best Corrected LNZ100 (n=49) LNZ101 (n=50) Placebo (n=51) 20/15 No impact to distance vision in BETTER DISTANCE VISION normal light No impact to distance vision in low light Well tolerated, No drug related serious adverse ev
Slide 18: European historical use of 400M doses confirms expected low side effect profile
European historical use of 400M doses confirms expected low side effect profile Long history of use for Glaucoma • Approved for Glaucoma in Europe in 1970’s5 • Approved at higher concentration and QID dosing5 • Marketed in 12 European countries and 400M doses • Rapid anterior chamber penetration5 •
Slide 19: Management and Board
Management and Board Management: Eef Schimmelpennink Shawn Olsson Marc Odrich, MD Marv Garrett Gerald Horn, MD Melissa Rosness Kyle Casement President and CEO Chief Commercial Officer Chief Medical Officer SVP Regulatory & Senior Scientific VP CMC & Manufacturing VP Finance Quality Advisor & Founder
Slide 20: Medical Advisors
Medical Advisors Ophthalmology: Steven Dell, MD Deepinder Dhaliwal, MD John Doane, MD Kathryn Hatch, MD Terry Kim, MD Colman Kraff, MD Robert Osher, MD Medical Director UPMC Eye Center Discover Vision Centers Mass. Eye and Ear. Asst. Prof. Prof. of Ophthalmology Kraff Eye Institute Cincinnati Eye In
Slide 21: References
References 1. Progression of Near Vision Loss and Incidence of Near Vision Impairment in an Adult Chinese Population, Han, Xiaotong, et al, Ophthalmology, 124(5): page 734, May 2017 2. Global Prevalence of Presbyopia and Vision Impairment from Uncorrected Presbyopia, Fricke, Timothy, et al, American
LENZ Therapeutics — Investor Presentation (November 2023) on 6ix